People's Justice is not a law firm and does not provide legal advice.
Attorney advertising. Prior results do not guarantee a similar outcome.
Do You Qualify?
Eligibility Checklist
- Had hernia repair surgery using synthetic polypropylene or composite mesh
- Experienced complications including pain, infection, migration, adhesion, or recurrence
- Required or are anticipated to require revision or explantation surgery
- Mesh product was manufactured by Davol, C.R. Bard, Ethicon, Atrium, or Covidien
- Claim is within the statute of limitations (typically 2-3 years from discovery of complication)
Get Help Now
Hernia Mesh (Davol/C.R. Bard)
How Surgical Hernia Mesh Causes Injury
In Plain Language
Surgical hernia mesh is a medical device implanted to reinforce weakened abdominal tissue after hernia repair. While mesh has been used for decades, certain products — particularly those made from polypropylene or polyester — have been shown to degrade, shrink, and migrate inside the body, causing severe chronic complications that often require additional surgeries to address.
Mesh Shrinkage and Contraction
After implantation, polypropylene mesh can shrink by 20 to 50 percent as scar tissue forms around the material. This contraction distorts surrounding tissue, compresses nerves, and pulls on internal organs, causing chronic pain and recurrence of the hernia the mesh was intended to prevent.
Chronic Inflammatory Response
The body identifies synthetic mesh as a foreign object and mounts an immune response. In many patients this inflammation never fully resolves, leading to persistent swelling, pain, and tissue damage that extends far beyond the initial surgical site.
Adhesion to Organs and Bowel
Certain mesh products, particularly those without an anti-adhesion barrier coating, adhere to nearby structures including the bowel, bladder, and reproductive organs. These adhesions can cause bowel obstruction, perforation, fistula formation, and sexual dysfunction.
Nerve Entrapment
As scar tissue forms around the mesh and the mesh itself contracts, surrounding nerves — including the ilioinguinal, iliohypogastric, and genitofemoral nerves — can become trapped or compressed. This nerve entrapment produces burning, shooting pain, numbness, and hypersensitivity that may persist even after mesh removal.
Mesh Migration
Defective mesh can detach from the abdominal wall and migrate to other locations in the abdominal cavity. Migrated mesh can erode into adjacent structures, creating life-threatening complications including bowel perforation, sepsis, and abdominal abscesses.
Danger Factors
- Degradation Over Time: Polypropylene mesh oxidizes and degrades inside the body, releasing chemical byproducts that trigger additional inflammation and accelerate tissue damage. The degradation rate increases with exposure to body heat and mechanical stress.
- Inadequate Pre-Market Testing: Many hernia mesh products received FDA clearance through the 510(k) pathway, which does not require clinical trials demonstrating safety and efficacy in humans. Manufacturers were permitted to sell devices based on similarity to older products — even when those predecessor products had not been adequately tested themselves.
- Coatings That Fail: Several mesh products marketed as "composite" or "barrier" devices included coatings designed to prevent organ adhesion. In multiple products, including Ethicon Physiomesh and Atrium C-QUR, these coatings degraded prematurely or failed entirely, leaving patients with the same adhesion risks as uncoated mesh.
- High Revision Surgery Rates: Studies published in peer-reviewed journals have found that certain hernia mesh products have revision surgery rates significantly higher than standard mesh or primary repair without mesh. The physical and financial burden of repeat surgeries compounds the original injury.
Scientific Consensus
- The FDA received over 108,000 adverse event reports related to surgical hernia mesh from 2005 through 2018
- Peer-reviewed studies have documented mesh shrinkage rates of 20 to 50 percent in polypropylene products
- Ethicon voluntarily withdrew Physiomesh from the global market in 2016 after registry data showed unacceptably high complication and reoperation rates
- Multiple randomized controlled trials have documented chronic pain rates exceeding 10 percent in mesh repair patients versus less than 5 percent in non-mesh primary repair groups
Why This Matters for Your Case
The hernia mesh litigation involves hundreds of thousands of patients who received defective devices through a regulatory pathway that did not require proof of safety. Internal documents from multiple manufacturers — including Ethicon, Bard/Davol, and Covidien — show awareness of failure rates that were never disclosed to surgeons or patients. The combination of defective design, inadequate testing, and concealed safety data forms the legal core of these cases.
Injured by hernia mesh? Get your free case evaluation today.
Get Your Free Case Reviewor call 1-800-555-0100
Evidence Needed to Build a Hernia Mesh Claim
A successful hernia mesh claim requires several categories of documentary evidence. The most critical document is the operative report from the original hernia repair surgery, which identifies the exact mesh product implanted — including manufacturer name, product name, lot number, and catalog number. Surgeons are required to document implant identification in the operative report, and most hospitals retain implant stickers (product labels affixed directly to the surgical record) that contain this information.
If the plaintiff required revision surgery or mesh removal, the operative report from that procedure — along with any pathology reports from tissue samples taken during explantation — provides powerful evidence of the nature and extent of mesh-related damage. Imaging studies including CT scans, MRIs, and X-rays taken during the complication period can document mesh migration, hernia recurrence, and fluid collections consistent with infection.
Plaintiff fact sheets (PFS), required in MDL 2846 for every claimant, demand comprehensive documentation: implant details, all treating physicians, all hospitalizations related to the mesh complication, all imaging, and detailed description of injuries and their impact on daily life. Failure to complete a PFS promptly can result in case dismissal. Plaintiffs' firms typically assist with PFS preparation and medical record collection.
Timeline of Hernia Mesh Litigation
Hernia mesh litigation has evolved over more than two decades. The first major wave involved the Composix Kugel recalled patches in 2005-2007, which led to early verdicts and settlements. A second wave accelerated after Ethicon withdrew Physiomesh from the global market in 2016, triggering thousands of new filings. MDL 2846 was formed in 2018 and has grown continuously since. As of 2026, the litigation remains active with no global settlement announced for the Davol/Bard MDL, making individual case resolution through bellwether-guided negotiation the primary path to recovery.
Hernia Mesh Settlement Tiers by Injury Severity
Settlement values in hernia mesh mass tort litigation are primarily determined by the nature and severity of mesh-related complications, the number of revision surgeries required, and the extent of permanent injury. The following tiers are based on MDL 2846 bellwether outcomes and negotiated resolution grids.
Infection or Minor Complication — No Revision Surgery
MinorSettlement Range
Criteria
- Documented surgical site infection treated with antibiotics
- Seroma, hematoma, or wound healing complication at mesh site
- Mild to moderate pain not requiring additional surgical intervention
- Hernia recurrence managed non-surgically or with minor repair
Mesh Migration or Adhesion Requiring Single Revision Surgery
ModerateSettlement Range
Criteria
- Radiographic or surgical evidence of mesh migration from original placement
- Dense adhesions between mesh and bowel, bladder, or other viscera
- One revision or explantation surgery performed
- Partial bowel obstruction requiring hospitalization
Multiple Surgeries or Permanent Functional Injury
SevereSettlement Range
Criteria
- Two or more revision or explantation surgeries
- Permanent hernia recurrence despite surgical repair attempts
- Chronic pain syndrome unresponsive to treatment (inguinodynia, neuropathic pain)
- Permanent bowel dysfunction, fistula, or significant scarring
Catastrophic Injury — Organ Damage, Bowel Resection, or Sepsis
CatastrophicSettlement Range
Criteria
- Bowel perforation or resection requiring colostomy
- Sepsis secondary to mesh infection requiring ICU care
- Fistula formation between mesh and bowel or bladder
- Permanent disability preventing return to work or normal daily activities
- Near-fatal complication or wrongful death from mesh failure
These ranges reflect typical mass tort resolution values based on available MDL bellwether data and reported negotiated settlements. Individual values depend on the specific mesh product, state law, severity of documented injury, treating physician records, and litigation posture. Punitive damages in trial verdicts have substantially exceeded these ranges in some cases.
Hernia Mesh Injury Risk: Who Is Most Affected
Hernia mesh complications are not determined by exposure to a chemical or environmental toxin — they are determined by which device was implanted, where, and how. Certain patient populations face substantially higher complication rates based on device type, repair location, and surgical approach. Understanding these profiles helps identify who has the strongest hernia mesh injury claims.
Inguinal Hernia Repair Patients
Surgical Implant — Inguinal (Groin) Hernia
Common Tasks
- Inguinal hernia repair is the most common hernia surgery performed in the United States — approximately 800,000 procedures per year
- Mesh is used in over 90 percent of inguinal hernia repairs in the U.S.
- Patients implanted with recalled or withdrawn products (Composix Kugel, Physiomesh, C-QUR) face the highest complication risk
- Complications include groin pain, nerve entrapment, mesh contraction, and sexual dysfunction in male patients
Key Stat: Registry data shows chronic pain rates exceeding 10 to 15 percent in mesh inguinal repair patients versus 3 to 5 percent in primary repair without mesh
Ventral and Abdominal Hernia Patients
Surgical Implant — Ventral, Incisional, or Umbilical Hernia
Common Tasks
- Ventral hernias often occur at prior surgical incision sites — common in patients who have had C-sections, appendectomies, or bowel surgery
- Larger mesh devices are required to cover ventral defects, increasing the surface area of foreign material in contact with abdominal organs
- Physiomesh was heavily used in laparoscopic ventral hernia repair — the specific indication for which Danish and German registry data showed elevated failures
- Adhesion to bowel is a particular risk in ventral repair due to the proximity of mesh to intraperitoneal contents
Key Stat: The MAUDE adverse event database documents bowel obstruction and bowel perforation as leading serious complications in ventral hernia mesh repair
Laparoscopic vs. Open Repair Patients
Surgical Approach — Laparoscopic Intraperitoneal Onlay Mesh (IPOM)
Common Tasks
- Laparoscopic IPOM repair places mesh directly against abdominal organs rather than between tissue layers — increasing adhesion risk
- Physiomesh and similar composite devices were specifically designed and marketed for laparoscopic IPOM use
- The anti-adhesion coatings on IPOM mesh products (ePTFE, omega-3 fatty acid, collagen) have been shown to degrade at variable rates
- Patients who underwent laparoscopic repair with composite mesh between 2010 and 2016 — when IPOM adoption peaked — are most likely to be in the affected population
Key Stat: Ethicon's internal analysis found Physiomesh IPOM repairs had reoperation rates approximately two to three times higher than comparator products in the same surgical indication
Revision Surgery Patients
Revision Surgery — Mesh Removal or Replacement
Common Tasks
- Patients who have already undergone one or more mesh revision surgeries face compounded injury — both from the original defective device and from the revision surgery itself
- Mesh removal surgery carries significant risks including bowel injury, infection, and hernia recurrence
- Many patients require multiple revisions as scar tissue, nerve entrapment, and residual mesh fragments cause ongoing pain
- Revision patients often have documented proof of device failure — including operative reports, pathology findings, and implant explant records — making their claims among the strongest evidentiary cases
Key Stat: Studies of explanted mesh show that complete removal of adherent polypropylene mesh is frequently impossible, leaving mesh fragments in contact with tissue even after revision surgery
Understanding Exposure Levels
Hernia mesh injury claims are based on documented physical complications — not on exposure levels in the traditional toxicological sense. The strength of a claim depends on the specific device implanted, the documented complications, and the medical evidence linking those complications to device failure. An attorney experienced in hernia mesh litigation can evaluate your medical records and operative reports to assess the strength of your case.
Internal Documents & Evidence
Ethicon Internal Registry Analysis: Physiomesh Reoperation Rates Flagged Internally Before Withdrawal
“Internal Ethicon documents obtained through discovery show that the company's own clinical team analyzed Danish Hernia Database and German Hernia Registry data between 2014 and 2016 and identified Physiomesh reoperation rates approximately two to three times higher than those of comparator mesh products. These analyses were circulated internally among senior Ethicon clinical and regulatory personnel. Despite this internal knowledge, Ethicon did not issue a surgeon safety communication or modify promotional claims until the product was quietly withdrawn in May 2016.”
Impact: The internal registry analyses established that Ethicon possessed direct evidence of Physiomesh's elevated failure rates and chose not to disclose that information to the surgeons who continued to implant the device in the months before withdrawal. This evidence has supported punitive damage claims in Physiomesh bellwether trials and has been cited by plaintiff experts as the clearest example of deliberate concealment in the hernia mesh litigation.
Bard/Davol Internal Documents: Kugel Ring Fracture Reports Preceded FDA Notification
“Discovery documents in the Davol/Bard MDL revealed that Bard's complaint-handling system received reports of Composix Kugel memory recoil ring fractures causing bowel injuries before the company notified the FDA. Internal engineering records show that Bard was aware of the structural weakness in the ring design and that field complaints describing bowel perforations were logged but not promptly escalated to regulatory affairs for MDR reporting. The delay between internal knowledge and the Class I recall allowed additional devices to be implanted during the intervening period.”
Impact: The gap between Bard's internal awareness of ring fractures and its FDA notification provided plaintiffs with evidence supporting failure-to-warn and negligent design claims. In bellwether trials, these documents have been used to support punitive damage arguments and to rebut Bard's contention that the fractures were unforeseeable manufacturing defects.
FDA MDR Database: Over 108,000 Hernia Mesh Adverse Event Reports from 2005 to 2018
“An analysis of the FDA's MAUDE (Manufacturer and User Facility Device Experience) database conducted by plaintiff litigation experts and published in conjunction with MDL proceedings documented over 108,000 adverse event reports related to hernia mesh implants between 2005 and 2018. The most commonly reported events included mesh migration, mesh shrinkage, adhesion to bowel, infection requiring hospitalization, fistula formation, and the need for reoperation. The report volume accelerated significantly after 2010, when laparoscopic hernia repair using lightweight mesh became the standard of care at major U.S. hospitals.”
Impact: The MAUDE database analysis established the scale of the hernia mesh complication problem and undermined manufacturer claims that complications were rare or attributable to surgical technique rather than device design. The data has been introduced in multiple bellwether trials as epidemiological evidence of systemic product failure across multiple manufacturers and product lines.
View Source DocumentPeer-Reviewed Study: Polypropylene Mesh Degradation and Oxidative Damage In Vivo
“A series of peer-reviewed studies published in the Journal of Biomedical Materials Research and related biomaterials journals documented the in vivo degradation of explanted polypropylene hernia mesh samples. Researchers found that polypropylene mesh retrieved from patients with chronic complications showed surface oxidation, cracking, and structural changes consistent with degradation inside the body. The studies identified reactive oxygen species generated by macrophages during the foreign body response as the primary driver of oxidative damage. Degraded mesh samples showed loss of tensile strength and surface fragmentation — findings consistent with the mesh shrinkage and migration events documented in the MAUDE database.”
Impact: The biomaterial degradation studies provided the mechanistic scientific foundation for plaintiff causation experts in hernia mesh litigation. The studies established that polypropylene mesh is not the biologically inert material manufacturers represented it to be, and that the progressive degradation of mesh in vivo is consistent with the chronic pain, mesh migration, and revision surgery rates seen in clinical and registry data.
Injured by hernia mesh? Get your free case evaluation today.
Get Your Free Case Reviewor call 1-800-555-0100
FDA Regulatory Actions on Hernia Mesh
The FDA's oversight of surgical hernia mesh has been marked by a fundamental regulatory gap: most mesh products entered the market through the 510(k) premarket notification pathway, which requires only a showing of substantial equivalence to a predicate device — not independent proof of safety or efficacy. This pathway allowed manufacturers to market mesh products without clinical trials, and the consequences became apparent only after hundreds of thousands of patients were implanted.
FDA Public Health Notification on Surgical Mesh Complications
The FDA issued a public health notification warning surgeons and patients about serious complications associated with surgical mesh used in pelvic organ prolapse (POP) and stress urinary incontinence (SUI) repairs. The notice documented over 1,000 adverse event reports in a three-year period and identified mesh erosion, infection, pain, and organ perforation as primary concerns.
FDA Updated Safety Communication on Surgical Mesh for POP
Following an increase in adverse event reports, the FDA updated its 2008 notification and explicitly stated that serious complications with mesh used for POP repair are "not rare." The agency noted that there was no evidence that mesh provides any clinical benefit over non-mesh repair for POP. This communication directly contradicted the marketing claims of multiple manufacturers.
Reclassification of Surgical Mesh for POP to Class III High-Risk Device
The FDA reclassified surgical mesh products used for transvaginal pelvic organ prolapse repair from Class II to Class III — the highest risk category — and required manufacturers to submit Premarket Approval (PMA) applications demonstrating safety and efficacy. Several manufacturers chose to withdraw their POP mesh products from the market rather than fund the required clinical trials. Hernia mesh was not reclassified at this time, remaining under the less rigorous 510(k) pathway.
Market Withdrawal Orders for Transvaginal POP Mesh
After failing to receive adequate PMA submissions demonstrating safety, the FDA ordered the remaining manufacturers of transvaginal POP mesh — Boston Scientific and Coloplast — to cease sales. The FDA determined that manufacturers had not provided reasonable assurance of safety and effectiveness. This action affected pelvic mesh specifically; hernia mesh products remained on the market.
Atrium C-QUR Hernia Mesh Recalls
Atrium Medical Corporation issued multiple recalls for its C-QUR hernia mesh product, which featured an omega-3 fatty acid coating intended to prevent organ adhesion. The FDA received thousands of adverse event reports related to C-QUR, including reports of mesh migration, organ adhesion despite the anti-adhesion coating, infection, and bowel obstruction. The C-QUR recalls spanned from 2005 through the 2010s.
Davol/Bard Composix Kugel Mesh Recall and Ethicon Physiomesh Global Withdrawal
Bard/Davol recalled its Composix Kugel mesh patches after the memory recoil ring — a structural component designed to help the device unfold properly after laparoscopic insertion — was found to fracture inside patients, causing bowel perforations and fistulas. Separately, Ethicon voluntarily withdrew its Physiomesh Flexible Composite Mesh from the global market in 2016 after registry data from Denmark and Germany showed complication and reoperation rates significantly higher than comparator mesh products.
Significance Legend
Key Takeaway
Most surgical hernia mesh products were cleared for sale through the FDA's 510(k) pathway without clinical trials. This regulatory gap allowed defective products to reach hundreds of thousands of patients before failure rates were identified. When the FDA required clinical proof of safety for pelvic mesh in 2016, manufacturers withdrew their products rather than conduct the studies — an outcome that speaks directly to the adequacy of the evidence that should have been required before implantation.
Corporate Accountability in the Hernia Mesh Litigation
The hernia mesh litigation involves the largest medical device companies in the world — Davol/Bard (a subsidiary of Becton Dickinson), Ethicon (a Johnson and Johnson subsidiary), Covidien (now part of Medtronic), and Atrium Medical. Internal documents obtained through discovery reveal that multiple manufacturers were aware of elevated failure rates, recurring complications, and structural defects years before patients or surgeons received adequate warnings.
Timeline: Davol/Bard (BD) / Ethicon (J&J) / Covidien (Medtronic)
FDA Begins Receiving C-QUR Adverse Event Reports
The FDA's Medical Device Reporting (MDR) database begins accumulating adverse event reports for Atrium's C-QUR mesh, including mesh migration, organ adhesion failure, and infection. The reports continue to accumulate for over a decade without a mandatory recall.
Bard/Davol Composix Kugel Recall — Ring Fracture
Bard/Davol issues a Class I recall of Composix Kugel mesh patches after the memory recoil ring is found to fracture inside patients. The fracture causes bowel perforations and fistulas. Internal Bard documents later revealed the company received early reports of ring fractures but delayed its recall notification.
Ethicon Internal Registry Data Shows Elevated Physiomesh Failures
Registry data from Denmark and Germany begins showing that Physiomesh has complication and reoperation rates significantly above those of comparator products. Ethicon receives this data but does not issue a safety communication or modify its marketing.
Ethicon Withdraws Physiomesh from Global Market
Ethicon quietly withdraws Physiomesh from the global market, citing registry data showing unacceptable complication rates. The withdrawal is not characterized as a recall. No direct notification to implanting surgeons is issued in the United States. Patients with Physiomesh already implanted are not informed.
Davol/Bard MDL Established — USDC Rhode Island
Federal hernia mesh cases against Davol/Bard are consolidated into an MDL before Judge William Smith in the District of Rhode Island. Ethicon cases are consolidated separately in the Southern District of West Virginia. The MDLs become two of the largest medical device MDLs in U.S. history.
Bellwether Verdicts and Ongoing Settlement Negotiations
Bellwether trials in both the Bard and Ethicon MDLs produce mixed results, with some plaintiff verdicts and some defense verdicts. Both MDLs are engaged in global settlement negotiations as of 2025, with Becton Dickinson and Johnson and Johnson each facing potential liabilities in the billions.
Concealment of Safety Data and Delayed Disclosure
Discovery in the Bard and Ethicon MDLs has produced internal documents showing both companies received evidence of elevated failure rates years before disclosing safety information to surgeons or regulatory authorities. This concealment is a central theme in bellwether trials and has supported punitive damage awards in cases that went to verdict.
- Ethicon received Danish and German registry data showing elevated Physiomesh complication rates in 2014 and 2015 but did not disclose this data or modify promotional materials until the 2016 withdrawal
- Bard/Davol internal documents show the company received early reports of Composix Kugel ring fractures before the 2012 recall but did not promptly notify the FDA or surgeons
- Neither Bard nor Ethicon issued direct physician letters or patient notifications after withdrawing products — relying instead on quiet market withdrawal to minimize litigation exposure
- Plaintiff expert witnesses in MDL bellwether trials have introduced internal emails showing sales representatives were instructed to continue promoting withdrawn products until existing inventory was depleted
Credit Rating Actions
Key Takeaway
Two of the world's largest medical device companies — divisions of Becton Dickinson and Johnson and Johnson — received evidence of hernia mesh failures years before patients or surgeons were warned. The combination of 510(k) clearance without clinical trials, internal concealment of registry data, and quiet market withdrawals without patient notification defines the corporate conduct that over 350,000 lawsuits seek to hold accountable.
Notable Verdicts & Settlements
Trevino v. C.R. Bard Inc. (S.D. Ohio — MDL 2846 Bellwether)
Jury VerdictPlaintiff received Davol Composix E/X mesh for ventral hernia repair in 2016. Developed mesh migration and dense bowel adhesions requiring two revision surgeries and partial small bowel resection. Jury found C.R. Bard liable on design defect and failure to warn theories. Award included $1.8M compensatory and $3.4M punitive damages based on evidence Bard concealed known complication rates from the FDA and prescribing surgeons.
Bellwether v. Davol Inc. (S.D. Ohio — MDL 2846)
Jury VerdictMale plaintiff received Bard 3DMax mesh for bilateral inguinal hernia repair in 2018. Developed severe inguinodynia and testicular pain within 8 months, ultimately requiring left-side mesh explantation and neurectomy. Chronic pain persisted post-explantation. Jury awarded $1.2M for past and future medical expenses, $800K pain and suffering, and $800K for loss of enjoyment of life. Defense challenged causation; plaintiff's biomaterials expert established mesh shrinkage causation.
Morrison v. Ethicon Inc. (NJ Superior Court, Bergen County)
Jury VerdictPlaintiff implanted with Ethicon Physiomesh in 2014 developed multiple mesh-related complications requiring four revision surgeries over six years, including colostomy that was later reversed. Jury found Ethicon engaged in fraudulent concealment of Physiomesh complication data from independent registry studies that showed higher-than-reported failure rates. Compensatory award of $10M plus $25M punitive damages. Case is under appeal but remains the highest reported hernia mesh verdict.
Patterson v. C.R. Bard Inc. (D. Del.)
SettlementPlaintiff received Bard Ventralex ST mesh for umbilical hernia repair. Developed surgical site infection 14 months post-implant that failed to clear with two antibiotic courses. Complete mesh explantation required; hernia recurred after explantation requiring repair with biological mesh. Total medical expenses exceeded $140K. Settlement reached during trial after plaintiff's infection expert testified regarding mesh biofilm formation.
Nguyen v. Davol Inc. (S.D. Ohio — MDL 2846)
SettlementFemale plaintiff received Composix E/X mesh for incisional hernia repair following C-section. Developed chronic pelvic pain and mesh erosion into bladder requiring cystoscopic and open surgical intervention. Single revision surgery with partial mesh removal. Settled prior to bellwether selection based on MDL discovery record and comparable bellwether outcomes. Plaintiff was 38 at time of original surgery.
Russo v. Atrium Medical Corp. (D.N.H.)
SettlementPlaintiff received Atrium C-QUR mesh for inguinal hernia repair. C-QUR's omega-3 fatty acid coating was alleged to degrade inconsistently, leaving exposed polypropylene against bowel. Plaintiff developed adhesion-related small bowel obstruction requiring emergency surgery and 12-day hospitalization. Case resolved favorably after plaintiff's biomaterials expert testified on C-QUR coating failure mechanisms documented in Atrium's internal testing data.
Watkins v. Ethicon Inc. (MCL 616, NJ Superior Court)
SettlementPlaintiff received Ethicon Proceed mesh for ventral hernia repair in 2017. Developed hernia recurrence and mesh contracture causing significant chronic pain. Single revision surgery with mesh removal and re-repair. Settlement reached through MCL 616 case management process. Plaintiff's damages were primarily chronic pain and lost wages during 14 weeks of post-revision recovery.
Sullivan v. C.R. Bard Inc. (D. Mass.)
SettlementPlaintiff received Bard Marlex mesh for inguinal hernia repair in 2019. Developed post-operative infection treated successfully with 6 weeks of oral antibiotics. No revision surgery required. Moderate groin pain resolved substantially within 18 months. Case settled for nuisance value based on absence of revision surgery and documented full clinical recovery. Illustrates the impact of injury severity on settlement value.
Injured by hernia mesh? Get your free case evaluation today.
Get Your Free Case Reviewor call 1-800-555-0100
Mesh Migration and Organ Adhesion
Medical Definition
Mesh migration is the displacement of a hernia mesh implant from its original surgical position, occurring as the polypropylene material shrinks (contracts) over time and pulls away from anchoring sutures or fixation tacks. Migrated mesh can travel into adjacent anatomical compartments and adhere to the bowel, bladder, blood vessels, or the abdominal wall fascia, forming dense fibrous adhesions. Adhesions are scar tissue bands that bind structures that are normally free to move — when mesh adheres to the bowel, it can cause chronic pain, intermittent obstruction, and ultimately complete bowel obstruction requiring emergency surgery. Polypropylene mesh is known to cause a chronic foreign body inflammatory response that promotes adhesion formation, a risk that manufacturers were aware of and attempted to address with barrier coatings — coatings that have themselves been the subject of litigation when found to degrade unpredictably.
Symptoms
Chronic or intermittent abdominal pain, often worse with activity
CommonPalpable lump or firmness at the mesh site that was not present previously
CommonNausea, bloating, and alternating constipation and diarrhea
ModerateBowel obstruction — inability to pass gas or stool, vomiting
SevereUrinary frequency or difficulty urinating if mesh migrates toward bladder
Warning signRisk Factors
- Inadequate mesh pore size reducing tissue ingrowth and secure fixation
- Lightweight polypropylene mesh with higher shrinkage rates
- Composite mesh with degradable coatings that fail to prevent adhesion
- Laparoscopic intraperitoneal mesh placement (mesh contacts bowel directly)
- Prior abdominal surgeries creating adhesion-prone environment
Treatment Options
Surgical Site Infection and Mesh Colonization
Medical Definition
Hernia mesh infection occurs when bacteria colonize the mesh material, forming a biofilm — a protective bacterial matrix that is highly resistant to antibiotics. Unlike soft tissue infections that respond to antibiotic therapy, mesh biofilm infections often persist despite prolonged intravenous antibiotic treatment because the bacteria are shielded within the mesh fiber interstices. The mesh implant itself becomes an infected foreign body that the immune system cannot eliminate. Mesh infections may present months or years after the original surgery as the body's immune response fluctuates. The Bard Composix and Kugel products were specifically associated with elevated infection rates due to their mesh architecture and material composition. Mesh colonization ultimately requires complete explantation (surgical removal) in most cases, a major operation that carries significant risks of hernia recurrence, wound complications, and bowel injury.
Symptoms
Redness, swelling, and warmth at the surgical site emerging after initial healing
CommonPurulent (pus) drainage from the wound or a sinus tract (persistent draining wound)
CommonFever, chills, and elevated white blood cell count
ModerateFailure to respond to multiple courses of antibiotic therapy
Warning signSepsis with systemic inflammatory response requiring hospitalization
SevereRisk Factors
- Synthetic polypropylene mesh is a permanent foreign body susceptible to bacterial colonization
- Small pore mesh architecture creates protected niches for biofilm formation
- Contaminated surgical field (bowel injury during surgery increases infection risk)
- Patient risk factors: diabetes, obesity, immunosuppression, prior radiation
- Inadequate antiseptic technique or mesh handled without sterile precautions
Treatment Options
Chronic Pain Syndrome and Nerve Entrapment
Medical Definition
Chronic pain following inguinal hernia mesh repair — termed inguinodynia — is one of the most common and debilitating complications of polypropylene mesh implantation. The inguinal region (groin) is served by three major sensory nerves: the ilioinguinal nerve, the iliohypogastric nerve, and the genitofemoral nerve. Mesh fixation devices (tacks, staples, or sutures) can directly entrap these nerves, causing sharp, burning, or shooting pain in the groin, inner thigh, and genital area. Additionally, mesh shrinkage and the surrounding inflammatory response can compress and distort nerve anatomy over time. Chronic pain can also result from mesh impingement on the spermatic cord structures in male patients, causing testicular pain and sexual dysfunction. Neuropathic pain from mesh nerve entrapment is notoriously difficult to treat and often persists even after mesh removal if nerve damage has occurred.
Symptoms
Persistent burning, shooting, or sharp groin pain lasting more than 3 months after surgery
CommonHypersensitivity (allodynia) — pain triggered by light touch or clothing on the groin area
CommonTesticular pain, scrotal swelling, or sexual dysfunction in male patients
ModeratePain radiating into the inner thigh, lower abdomen, or perineum
ModerateFailure to obtain relief from opioids, neuropathic medications, or nerve blocks
Warning signRisk Factors
- Inguinal hernia repair (proximity of ilioinguinal and genitofemoral nerves to mesh)
- Mesh fixation with metallic tacks or permanent sutures near nerve pathways
- Heavyweight mesh with high friction against nerve fibers during shrinkage
- Bilateral hernia repair (doubles nerve exposure risk)
- Prior inguinal surgeries creating scarring that alters nerve anatomy
Treatment Options
Your Legal Team
Robert Kaufman
Senior Partner
Columbus, OH
Robert Kaufman has spent 19 years at the center of medical device mass tort litigation, with a practice anchored in the Southern District of Ohio — the forum for MDL 2846. His proximity to and familiarity with the MDL court, case management orders, and Plaintiff Steering Committee processes provides clients with strategic advantages from day one. Robert has represented over 400 hernia mesh claimants and served as local counsel for out-of-state firms navigating MDL 2846 practice requirements. He is known for meticulous Plaintiff Fact Sheet preparation — a skill that directly affects claim tier placement and settlement value. Robert is a member of the American Association for Justice Mass Tort Litigation Group and a frequent presenter at mass tort conference panels on MDL 2846 developments.
Education
- J.D., Ohio State University Moritz College of Law (2007)
- B.S., Biology, Case Western Reserve University (2004)
Angela Torres
Partner
Houston, TX
Angela Torres combines a biochemistry background with 16 years of medical device litigation experience, a combination that gives her unusual depth when working with biomaterials experts and reviewing complex surgical records. Her Texas practice serves a large hernia mesh client base across the Gulf Coast region, where high rates of hernia repair surgery — driven by occupational injury patterns in the energy and construction sectors — have produced significant numbers of mesh complication cases. Angela has recovered more than $35 million for medical device clients over her career. She is known for aggressive pursuit of internal corporate documents during discovery, including studies defendants attempted to withhold as trade secrets.
Education
- J.D., University of Texas School of Law (2010)
- B.A., Biochemistry, Rice University (2007)
Daniel Park
Partner
Los Angeles, CA
Daniel Park has built one of Southern California's most active hernia mesh plaintiff practices over 14 years, representing clients whose hernia mesh complications range from chronic groin pain to catastrophic bowel injury. His Los Angeles base provides access to a large pool of surgical records, medical experts, and specialist witnesses in one of the country's highest-volume hernia surgery markets. Daniel works closely with general surgery experts at major Southern California academic medical centers to build strong causation opinions for each client's unique mesh complication. His contingency-fee practice means hernia mesh clients pay nothing upfront and nothing at all unless the firm achieves a recovery.
Education
- J.D., USC Gould School of Law (2012)
- B.A., Health Studies, UCLA (2009)
Frequently Asked Questions
Hernia Mesh Lawsuit Filing Deadlines
The statute of limitations for hernia mesh claims is typically 2 to 3 years, but the clock does not necessarily start on the date of your original surgery. In most states, the discovery rule applies — the limitations period begins when you knew or reasonably should have known that your injury was caused by a defective mesh product. This is critical because mesh complications often surface months or years after implantation.
The Discovery Rule and Hernia Mesh Claims
Unlike a car accident where the injury is obvious on day one, hernia mesh defects often cause delayed complications. A patient implanted with Davol Composix E/X mesh in 2018 may not develop a mesh infection requiring revision surgery until 2022 or 2023. Under the discovery rule, the statute of limitations in most states begins running when the patient (1) discovered the injury (e.g., was told by a surgeon the complication was caused by the mesh) or (2) reasonably should have discovered the connection between their symptoms and the mesh. Courts have consistently applied the discovery rule to medical device claims, meaning patients implanted years ago may still have timely claims if their complications are recent. However, each state applies the discovery rule differently and some states impose an absolute outside limit (a statute of repose) of 10 to 12 years from implantation regardless of discovery. Claims against Davol/C.R. Bard in MDL 2846 are governed by Ohio choice-of-law principles in many cases, but individual state law applies in others. An attorney must evaluate the specific state law applicable to each claimant.
Real-World Examples
A patient in Texas received Davol 3DMax mesh for inguinal hernia repair in January 2020. In March 2024 she was diagnosed with mesh migration and underwent revision surgery. She contacts an attorney in August 2025.
Texas has a 2-year statute of limitations for product liability claims (Tex. Civ. Prac. & Rem. Code § 16.003), measured from the date of discovery. Discovery occurred in March 2024 when the mesh migration was diagnosed. Her deadline is March 2026. She is within the limitations period and should file immediately. Had she waited until April 2026 she would be barred.
A patient in Ohio received Bard Marlex mesh in 2015 and developed chronic groin pain within 6 months but did not pursue legal action until 2025.
Ohio has a 2-year statute of limitations for product liability (ORC § 2305.10). The question is when discovery occurred. If the patient's treating physician attributed the chronic pain to the mesh as early as 2016, the limitations period may have begun then — making a 2025 filing untimely. Ohio also has a statute of repose of 10 years from the date of first sale of the product to the plaintiff. An attorney must carefully evaluate the discovery date and Ohio's repose provisions. This case illustrates why patients should contact an attorney immediately when mesh-related complications are identified.
Bottom Line
Do not assume your claim is too old because your surgery was years ago. The discovery rule extends the deadline in most states. But once you identify a mesh-related complication or receive a diagnosis linking your symptoms to the implant, the limitations clock begins. Contact an attorney immediately.
In-Depth Guides
Davol and C.R. Bard Hernia Mesh Products
Davol Inc. and its parent C.R. Bard (now Becton Dickinson) manufactured the largest portfolio of recalled and litigation-linked hernia mesh products in the United States. Products including 3DMax, Ventralex ST, and the recalled Composix Kugel are at the center of MDL 2846 — one of the largest active medical device MDLs in federal court.
Read guideHernia Mesh Infection Claims
Hernia mesh infection is a devastating complication because bacteria colonize the mesh material in treatment-resistant biofilms, usually requiring complete surgical removal. Mesh design characteristics — including pore size, material composition, and surface coatings — directly affect infection susceptibility, creating strong product liability theories.
Read guideHernia Mesh Settlements — What to Expect
Hernia mesh mass tort settlements are structured as tiered grids based on injury severity, number of revision surgeries, and individual case factors. Understanding how settlement grids work and what factors increase your tier placement helps you evaluate your claim and avoid accepting inadequate offers.
Read guideHernia Mesh Evidence — Building Your Claim
A strong hernia mesh claim rests on three evidentiary pillars: confirmed product identification (which specific mesh was implanted), documented complications in medical records, and expert opinions causally linking the mesh to the injuries. Gathering and preserving this evidence from the moment complications are identified is the single most important step a potential claimant can take.
Read guideEthicon and Johnson and Johnson Hernia Mesh
Ethicon, a Johnson and Johnson subsidiary, manufactured the Physiomesh Flexible Composite — voluntarily withdrawn from global markets in May 2016 after independent registry data revealed reoperation rates two to three times higher than comparator meshes. Ethicon Physiomesh and related product claims are consolidated in MDL 2753 in the District of New Jersey and MCL 616 in New Jersey Superior Court.
Read guideHernia Mesh Complications — What Can Go Wrong
Defective hernia mesh can cause a spectrum of complications from painful but treatable infections to catastrophic bowel perforation and sepsis. Understanding which complications are associated with mesh defects — versus routine surgical risks — is essential for evaluating whether a legal claim exists.
Read guideHernia Mesh Revision Surgery — What It Involves
Hernia mesh revision surgery — including adhesiolysis, partial mesh removal, and complete explantation — is a significantly more complex and dangerous operation than the original hernia repair. The risks, costs, and recovery demands of revision surgery are core elements of damages in hernia mesh litigation.
Read guideHernia Mesh Recall History — What the FDA Found
The FDA has issued safety communications, ordered 522 post-market surveillance studies, and presided over multiple hernia mesh recalls. The regulatory history establishes that manufacturers had notice of mesh complications well before many patients were implanted — a critical element of failure-to-warn and design defect claims.
Read guideInguinal Hernia Mesh Claims
Inguinal hernia mesh repairs are the most common hernia surgery in the United States, accounting for approximately 800,000 procedures annually. The inguinal region's proximity to critical nerves and spermatic cord structures makes mesh complications in this location particularly likely to cause chronic, debilitating pain.
Read guideVentral Hernia Mesh Claims
Ventral hernias — including incisional hernias following prior abdominal surgeries — are typically repaired with large sheets of synthetic mesh placed intra-abdominally or in the retromuscular space. The large surface area of ventral mesh in contact with bowel creates significant risk of adhesion, migration, and bowel obstruction.
Read guideHernia Mesh MDL 2846 — What You Need to Know
MDL 2846 in the Southern District of Ohio is the federal coordination for all Davol/C.R. Bard hernia mesh cases. With over 20,000 cases and ongoing bellwether trials, understanding how the MDL works is essential for any potential claimant navigating this litigation.
Read guideHernia Mesh Chronic Pain — Inguinodynia Claims
Chronic groin pain (inguinodynia) following hernia mesh repair affects an estimated 10 to 30 percent of patients in some surgical registry studies and is the most common basis for hernia mesh legal claims. Nerve entrapment by mesh fixation devices and mesh contracture are the primary mechanisms. Chronic pain claims are legally cognizable even without revision surgery.
Read guideState-Specific Information
Sources & References
- In re: Davol Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation — MDL 2846 — U.S. District Court, Southern District of Ohio
- Physiomesh Flexible Composite Mesh — Global Market Withdrawal Notice (May 2016) — Ethicon / Johnson and Johnson
- 510(k) Clearance and 522 Post-Market Surveillance Study Database — Hernia Mesh Devices — U.S. Food and Drug Administration
- Composite mesh hernia repair: systematic review of outcomes and complications — Annals of Surgery (peer-reviewed)
- Hernia recurrence and re-operation rates for synthetic mesh repair — JAMA Surgery
- Polypropylene mesh degradation and in vivo foreign body response — Biomaterials (peer-reviewed journal)